M&A
Sanofi Weighs Insmed Takeover
Sanofi is reportedly evaluating a potential acquisition of Insmed, but no agreement or formal offer has been announced. Insmed's shares rose as much as 20.58% intraday, bringing its market capitalization to approximately $31.7 billion.
Its respiratory portfolio includes Brinsupri, Arikayce and phase 3 candidate TPIP. A potential deal could help Sanofi prepare for Dupixent's future patent expirations, but a valuation approaching $40 billion could challenge its financing and capital allocation.
Written by Gosset from public sources. Source types: News article. Sources are available to Gosset users. Log in to see them.